Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | CA9 | Q16790 | 4/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | PYGB | P11216 | 6/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9616492 | 1.00 | CA1 (0.50) | CA1CA2CA9AKR1B1PYGB | |
| SCHEMBL18642492 | 1.00 | CA1 (0.50) | CA1CA2CA9AKR1B1PYGB | |
| SCHEMBL7253811 | 1.00 | CA1 (0.50) | CA1CA2CA9AKR1B1PYGB | |
| SCHEMBL3810831 | 1.00 | CA1 (0.50) | CA1CA2CA9AKR1B1PYGB | |
| SCHEMBL3810098 | 0.89 | PNP (0.40) | CA1CA2CA9AKR1B1PYGB | |
| SCHEMBL5189446 | 0.87 | AKR1B1 (0.53) | CA1CA2CA9AKR1B1PYGB | |
| SCHEMBL4886455 | 0.86 | CA1 (0.37) | CA1CA2CA9AKR1B1PYGB | |
| SCHEMBL7893924 | 0.86 | CA1 (0.47) | CA1CA2CA9AKR1B1PYGB | |
| SCHEMBL9051986 | 0.86 | AKR1B1 (0.49) | CA1CA2CA9AKR1B1PYGB | |
| SCHEMBL8041486 | 0.86 | AKR1B1 (0.49) | CA1CA2CA9AKR1B1PYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140186306-A1 | NOVEL AMPK AGONIST COMPOSITIONS AND METHODS OF USE | PLANTE PAUL RONALD (US) | 2014-07-03 | — | — | US | disclosed |
| EP-1370539-A1 | HIV INHIBITING N-AMINOIMIDAZOLE DERIVATIVES | K.U. Leuven Research and Development (BE) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002068395-A1 | HIV INHIBITING N-AMINOIMIDAZOLE DERIVATIVES | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2002-09-06 | — | — | WO | disclosed |
| EP-0495091-A4 | AICA RIBOSIDE ANALOGS | — | 1993-01-07 | — | — | EP | disclosed |
| EP-0495091-A1 | AICA RIBOSIDE ANALOGS | GENSIA, INC. (US) | 1992-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140186306-A1 | NOVEL AMPK AGONIST COMPOSITIONS AND METHODS OF USE | ADIPOR1, PRKAR2A, COL2A1 | CA1 4591/4885CA2 2560/4885CA9 4284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.